JCJoseph Cheaib

Joseph Cheaib

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joseph Cheaib has a total of 121 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The use of biparametric magnetic resonance imaging in active surveillance of prostate cancer

    by Carlos A. Rivera López, Michelle I. Higgins, Yuezhou Jing, Mark N. Alshak, Joseph G. Cheaib, Mufaddal Mamawala, Patricia Landis, Mohammad E. Allaf, Katarzyna J. Macura, Christian P. Pavlovich

    Objectives: This study aims to evaluate the performance of biparametric magnetic resonance imaging (bpMRI) compared to multiparametric MRI (mpMRI) for active surveillance (AS) in prostate cancer (PCa), focusing on lesion detection, PI‐RADS classification changes and grade reclassification (GR) rates. Methods: We retrospectively reviewed our institutional AS database for men who underwent mpMRI followed by bpMRI. Lesion counts and PI‐RADS classification were compared. Second, a subgroup of men who underwent mpMRI, biopsy, bpMRI and then repeat biopsy (‘bpMRI biopsy group’) was matched to a control group who underwent mpMRI, biopsy, another mpMRI and then repeat biopsy (‘mpMRI biopsy group’) based on age, PSA density, year of diagnosis and number of positive cores. GR rates at systematic and targeted biopsy of all PI‐RADS 3–5 lesions were compared, as were PI‐RADS changes. Results: A total of 129 men with a median of 29 months between mpMRI and bpMRI were included. mpMRI identified 77 PI‐RADS 3–5 lesions versus 114 on subsequent bpMRI (0.60 vs. 0.88 lesions/patient, p = 0.01); however, lesion distribution was similar, with rates of PI‐RADS 3, 4 and 5 lesions of 53%, 40% and 6% on mpMRI and 53%, 37% and 11% on subsequent bpMRI ( p = 0.87, 0.29 and 0.23, respectively). In the matched biopsy subgroups, when comparing men who had two surveillance mpMRIs with those who had a surveillance mpMRI followed by a surveillance bpMRI, lesion stability was not significantly different across PI‐RADS categories. GR at last biopsy occurred in 29% of the bpMRI biopsy group versus in 25% of the mpMRI biopsy group ( p = 0.7). Conclusions: bpMRI appears safe to incorporate into AS over the short term, as it was noninferior to mpMRI with similar GR rates and lesion stability.

  • Surgical Management of High-Risk Prostate Cancer

    by Joseph G. Cheaib, Mohamad E. Allaf

  • Survival outcomes after surgical treatment for non-clear cell renal cell carcinoma with tumor thrombus extension: a population-based cohort study

    by Joseph G. Cheaib, Carlos A. Rivera López, Craig Cronin, Mark N. Alshak, Adnan El-Achkar, Sunil H. Patel, Nirmish Singla

    To characterize the impact of histology on survival outcomes in a population-based cohort of patients treated surgically for renal cell carcinoma (RCC) with tumor thrombus (TT) extension. The Surveillance, Epidemiology, and End Results database was used to identify adult patients with node-negative, non-metastatic RCC and TT who underwent surgical resection between 2010 and 2021. The Kaplan-Meier method and log-rank test were used to compare overall survival (OS) probabilities for clear cell RCC (ccRCC) versus non-clear cell RCC (nccRCC). Cox and Fine-Gray competing risk regression analyses were performed to evaluate histology-specific risks of all-cause and cancer-specific mortality (CSM), respectively. A total of 6553 patients were included, of whom 381 (5.8%) had nccRCC. Over a median follow up of 3.2 years, 1757 (26.8%) deaths occurred, of which 1165 (66.3%) were attributable to RCC. There was no difference in OS between patients with ccRCC versus nccRCC (5-year OS: 70.9% versus 65.6%, p = 0.09). Histologic subtype was not significantly predictive of all-cause mortality on multivariable Cox regression (hazard ratio (HR) = 1.12, 95% confidence interval (CI): 0.92-1.37, p = 0.3). On multivariable competing risk regression analysis, nccRCC was not associated with increased hazard of CSM (HR = 1.24, 95% CI: 0.96-1.58, p = 0.09) compared to ccRCC. Similar findings were noted in the subcohort of patients with TT extension to the IVC. No statistically significant differences in survival outcomes by histology were detected among patients with TT arising from RCC after definitive surgical resection. Multimodal treatment strategies, particularly for nccRCC, are needed to further improve outcomes in these patients.

  • Non-surgical vs surgical management for major ischemic priapism of 36 hours duration

    by Adnan El-Achkar, Alyssa Arbuiso, Nilson Marquardt Filho, Joseph Cheaib, Isabella Florissi, Aurora Grutman, Arthur L Burnett

    Background: Ischemic priapism persisting beyond 36 hours frequently results in irreversible corporal injury and erectile dysfunction, raising questions about whether surgical intervention is even necessary or worthwhile in these cases. Aim: To compare outcomes of non-surgical vs surgical management in patients with ischemic priapism lasting ≥36 hours. Methods: We conducted a retrospective review of patients treated for ischemic priapism persisting ≥36 hours at our institution between January 2005 and October 2024. Patients were categorized into two cohorts based on initial treatment strategy: (1) non-surgical—aspiration with or without irrigation and phenylephrine injection and (2) surgical—T-shunt or Al-Ghorab shunt procedures, with or without corporal snaking, or penile prosthesis placement during the same admission. Demographic and clinical variables were compared using Wilcoxon-Mann–Whitney, Fisher’s exact, and chi-squared tests. Outcomes: Primary outcomes included reintervention and readmission rates; secondary outcomes included penile fibrosis and deformity. Results: Seventy-six patients were included: 38 treated non-surgically and 38 surgically. Baseline characteristics, including age, comorbidities, and priapism etiology, were similar between groups. Median duration of priapism at presentation did not differ significantly (36 vs 48 hours, P = 0.41). The non-surgical group had a significantly higher rate of readmission and reintervention compared to the surgical group (66.7% vs 10.4%, P < 0.01). Deforming penile fibrosis was more frequent in the non-surgical group (18.5% vs 7.9%), although this difference was not statistically significant (P = 0.309). Clinical Implications: Conservative non-surgical management for prolonged ischemic priapism is associated with higher retreatment rates and complications, suggesting that a more definitive surgical approach may be more effective in managing these cases. Strengths and Limitations: This study provides real-world comparative data on management strategies for prolonged ischemic priapism in a consecutive patient cohort. Limitations include its retrospective, single-center design, small sample size, and limited long-term follow-up, which precluded assessment of erectile function and prosthesis outcomes. Conclusion: In cases of ischemic priapism lasting >36 hours, non-surgical treatment is associated with higher failure and complication rates, supporting early surgical intervention to improve outcomes and reduce morbidity.

  • Cannabis use and risk of testicular germ cell tumour: a systematic review and meta‐analysis

    by Mehdi Kardoust Parizi, Ichiro Tsuboi, Akihiro Matsukawa, Alyssa Arbuiso, Joseph Cheaib, Shahrokh F. Shariat, Nirmish Singla

    Objectives: To systematically review and analyse the association of cannabis use with the risk of testicular germ cell tumour (TGCT), as studies have implicated an association between cannabis exposure and an increased risk of developing TGCT. Patients and Methods: The PubMed, Web of Science, and Cochrane Library databases were searched on November 2024 to identify eligible studies according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses statement and the Cochrane Handbook for Systematic Reviews of Interventions. Studies were selected that compared males (P: population) who had cannabis use (I: interventions) to non‐users or infrequent users of cannabis (C: comparators) with development of TGCT as the endpoint (O: outcomes) using multivariable analyses that adjusted for the effects of covariates (S: study type). The primary study outcome was the risk of TGCT among cannabis users. Available multivariable odds ratios (ORs) and hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were included in quantitative analysis. Results: A total of 86 articles were identified from our search, of which five were included for qualitative and quantitative analysis. Three studies were case–control and two were cohort in design. Current cannabis use was significantly associated with increased risk of TGCT (OR 1.62, 95% CI 1.13–2.31; P < 0.05 [two studies]), as was long‐term (≥10 years) cannabis use (OR 1.68, 95% CI 1.19–2.36; P < 0.05 [three studies]). In subgroup analysis, ever cannabis use was significantly associated with increased risk of non‐seminomatous germ cell tumour (NSGCT) (OR 1.71, 95% CI 1.12–2.60; P < 0.05 [two studies]). Conclusion: Our findings highlight cannabis use as a significant modifiable risk factor for the development of TGCT, particularly NSGCT. Given the increasing legalisation and availability of cannabis, further research is necessary to explore the underlying biological mechanisms and to confirm these associations across diverse populations.


  • Utilization patterns of second-generation androgen receptor pathway inhibitors as first-line therapy for prostate cancer in the United States

    by Aidan S. Weitzner, Soum D. Lokeshwar, Craig Cronin, Achyutha Kodavatikanti, Philipp Korn, Joseph G. Cheaib, Zhuo Tony Su, Nirmish Singla

    Background Second-generation androgen receptor pathway inhibitors (ARPIs) have transformed treatment for patients with advanced prostate cancer. Despite overlapping indications and comparable efficacy among these ARPIs, their staggered market entry and differing toxicity profiles may influence real-world prescribing. We characterized temporal trends and utilization patterns of these agents as frontline treatment for advanced prostate cancer in the United States. Methods Using the Merative MarketScan database, we identified patients with prostate cancer receiving enzalutamide, apalutamide, or darolutamide between 2012 and 2023. ARPI therapy was classified as first-line if initiated after ≥180 days of continuous enrollment. Annual proportions of first-line initiation and overall utilization of ARPIs were assessed descriptively. Comparisons by geographic status, urbanicity, insurance plan, and metastatic status were evaluated using chi-squared testing and multivariable modeling. Results Among 1.1 million individuals with prostate cancer, 3773 patients received ARPI therapy, of whom 1914 met criteria for first-line analysis. Use of first-line darolutamide steadily increased, rising to 42% in 2023 and surpassing enzalutamide. First-line ARPI selection did not differ significantly by region, urbanicity, insurance, or metastatic status. Overall ARPI utilization increased 21-fold over the study period, with enzalutamide remaining the most common agent. In 2023, a higher proportion of darolutamide fills occurred in metropolitan areas (p = 0.0008), and among metastatic patients (p = 0.0058). Conclusion Darolutamide rapidly emerged as the most selected first-line ARPI by 2023, without consistently observed differences by patient demographics. However, continued dominance of enzalutamide for overall fills may highlight durability of legacy therapy, particularly among non-metropolitan and non-metastatic populations.

  • Open Access

    Alcohol consumption among patients diagnosed with genitourinary cancers

    by Aidan Weitzner, Carlos Rivera Lopez, Joseph Cheaib, Michelle Higgins, Nirmish Singla

    Objective: To characterize alcohol consumption and binge‐drinking patterns among individuals with GU cancers (prostate, kidney, bladder and testicular) compared to a propensity‐matched cohort without cancer in a large, nationally diverse population.Materials and Methods: We conducted a retrospective, cross‐sectional study utilizing data from the National Institutes of Health All of Us Research Program. Matching accounted for age, sex assigned at birth, smoking status, comorbidities and education/marital status. The primary outcome was self‐reported drinking frequency. The secondary outcomes were self‐reported binge‐drinking frequency and Alcohol Use Disorders Identification Test (AUDIT‐C) scores.Results: Drinking and binge‐drinking among individuals with GU malignancy (N = 11 522) closely resembled those of matched controls (N = 47 747), with the majority (53%) consuming at least 2–4 drinks per month. There was no significant association between GU cancer diagnosis and increased drinking frequency (OR: 0.99; p = 0.65), binge‐drinking frequency (OR: 0.85; p: 0.055) or AUDIT‐C (OR: 0.99; p =0.65). Individuals diagnosed with kidney cancer had reduced odds of higher alcohol use (OR: 0.76; p < 0.001) and AUDIT‐C score (OR: 0.83; p < 0.001) compared to controls.Conclusion: In this large cohort, including traditionally underrepresented minorities, alcohol use was highly prevalent among those with GU malignancies. Drinking behaviours were similar to individuals without cancer, underscoring the need for integration of lifestyle‐focused interventions into survivorship care, as alcohol remains a common and modifiable behaviour with wide‐ranging health implications.


  • Prostate cancer active surveillance in solid organ transplant: a matched study and literature review

    by Mark N. Alshak, Michelle I. Higgins, Aurora J. Grutman, Jack Campbell, Joseph G. Cheaib, Carlos A. Rivera Lopez, Marcus Spann, Yuezhou Jing, Christian P. Pavlovich

    Objectives: To evaluate outcomes of prostate cancer (PCa) active surveillance (AS) in patients with versus without solid organ transplant (SOT), as the safety of PCa AS in patients with SOT remains understudied. We also performed a literature review to identify all studies describing PCa AS in patients with SOT. Patients and Methods: A retrospective study was conducted for patients with SOT (kidney, liver, heart, lung) with a diagnosis of PCa enrolled into AS either before or after SOT. Using prospectively collected information, they were matched with non‐SOT AS patients at PCa diagnosis by age, race, prostate‐specific antigen, and Gleason Grade Group (GGG). A scoping review was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. Results: A total of 32 SOT AS patients were matched with 99 non‐SOT AS patients. After matching, there was no significant difference in baseline demographics. 34% were enrolled into AS before SOT. The median time on AS for patients with and without SOT was 4.7 and 4.98 years, respectively ( P = 0.87). In all, 53% of patients with SOT and 54.5% those without SOT were still on AS ( P = 0.99). In all, 28.1% of patients with and 39.4% without SOT progressed to definitive treatment ( P = 0.30), and there were no differences in rates of grade re‐classification or GGG at definitive treatment. No systemic disease progression or PCa‐specific deaths occurred. In the literature, we identified and reviewed 11 studies and found 99 patients enrolled into AS either before ( n = 33) or after ( n = 66) SOT. We did not identify a safety signal. Conclusion: We present the largest series of patients with PCa on AS with SOT. In patients with SOT and PCa on AS, a surveillance strategy appears safe and has similar outcomes as those without SOT on AS. Our review found a paucity of AS data in the SOT setting suggesting that further research is warranted.


  • Open Access

    Supplementary Figures from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity

    by Roy Elias, Thomas Nirschl, Michael Rezaee, Anirudh Yerrapragada, Shirley Wang, Joseph Cheaib, Ridwan Alam, Sunil Patel, Yuezhou Jing, Mohamad Allaf, et al.

    WES QC 66 Patients (B = 34, W = 32) 123 Samples (57 T/N, 9T) RNAseq QC Avg.

  • Open Access

    Supplementary Tables from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity

    by Roy Elias, Thomas Nirschl, Michael Rezaee, Anirudh Yerrapragada, Shirley Wang, Joseph Cheaib, Ridwan Alam, Sunil Patel, Yuezhou Jing, Mohamad Allaf, et al.

    Supplementary Tables from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity